Zocor, Similar Cholesterol Drugs May Increase Aggression In Women: Study

Researchers from the University of California in San Diego indicate that some popular cholesterol drugs may raise aggressive tendencies among women, while decreasing those tendencies in men. 

In a study published last week in the science journal PLOS One, doctors are being urged to make sure patients are aware of the potential aggression side effects associated with the use of popular cholesterol fighting drugs known as statins.

Statins generate combined sales of more than $14.5 billion per year, and are used to block the body’s creation of cholesterol, which is a key contributor to coronary artery disease. Although the medications are widely used, a number of studies have linked statins to an increased risk of potentially serious injuries, including memory loss, muscle damage, kidney problems, and diabetes. The drugs include some of the most widely recognized brand name drugs in the U.S., including Lipitor, Crestor, Zocor, Vytorin, Prevachol and others.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In this latest study, researchers conducted a double-blind sex-stratified clinical trial on 1,016 adults, including 692 men and 324 postmenopausal women. Some of the subjects were given Zocor (simvastatin), others Pravachol (pravastatin), and some were given a placebo for six months. The researchers then assessed changes in aggression using what’s known as the Overt-Aggression-Scale-Modified-Aggression-Subscale (OASMa).

“In men, statins tended to decrease aggression, significantly so on pravastatin,” the researchers found, with those under the age of 40 experiencing greater reductions in aggression. “Statins (especially simvastatin) lowered testosterone, and increased sleep problems. Testosterone-drop on statins predicted aggression-decline.”

For women, the drugs appeared to have the opposite effect in the test, except for younger, surgically menopausal woman.

“The increase was significant, without exclusions, for women of more typical postmenopausal age,” the researchers concluded. “The aggression-increase in women on statins was stronger in those with low baseline aggression.”

Although statins are widely recommended within the medical community, they have been linked to several potential side effects.

The FDA has warned that statins may increase the risk of cognitive problems, and a study published in April also identified potential cognitive side effects of statins, along with an increased risk of diabetes, which researchers indicated may make the risks outweigh the benefits in some cases.

In February 2012, the FDA required the makers of statins to add new warnings about the potential impact of the medication on blood glucose levels. However, many critics have suggested that the warnings are not strong enough for certain medications, indicating that users and the medical community should be provided with more accurate information about the diabetes risks with Lipitor, Crestor and other statins.

Pfizer currently faces hundreds of Lipitor diabetes lawsuits filed by women throughout the United States, who allege that the drug maker knew or should have known about risks associated with their medication for years, but withheld diabetes warnings to avoid a negative impact on sales and growth of the blockbuster medication.

AstraZeneca also faces a number of Crestor lawsuits filed on behalf of former users of the cholesterol drug who were diagnosed with diabetes. Most of those cases are currently pending in California state court.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.